Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs Pricing of Entyvio, Imfinzi, Gazyva and More; Listing on Aug. 29
August 22, 2018
- MHLW OKs Opdivo’s Add’l Indications and Flat Dose, 1st-Line Tagrisso Use and More
August 22, 2018
- Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
August 22, 2018
- Impasse Continues over Mumps Vaccine Inclusion in Public Immunization Programs
August 20, 2018
- MHLW Panel to Review Kyorin’s OAB Drug Vibegron and More on Aug. 30
August 17, 2018
- MHLW Revving Up Biosimilar Drive with Educational Workshop for Healthcare Pros
August 17, 2018
- Astellas AML Drug, Pfizer’s Lorlatinib Up for MHLW Panel Review on Aug. 29
August 16, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
- Collaboration Research Project between Ministries Aims to Develop AI by FY2021 for Drug Discovery for Lung Cancer, IPF
August 16, 2018
- EFPIA Japan Proposes Establishing Organization Formed by Multiple Companies for Blood Collection Operation
August 10, 2018
- No Applications Yet for “Certificated Data Operator” under Medical Infrastructure Law; Govt Hoping for First Certification in FY2018
August 9, 2018
- First Drug Maker Applies to Use MID-NET: PMDA
August 7, 2018
- MHLW Panel Backs Lilly’s Ibrance Contender Abemaciclib for Breast Cancer
August 6, 2018
- Daiichi Sankyo's Herceptin Biosimilar Now in Line for September Approval as It Clears MHLW Panel
August 6, 2018
- MHLW Vaccine Panel to Continue Discussion on Pneumococcus in Elderly, Inactivated Polio Vaccine
August 3, 2018
- MHLW Panel Rebuffs Nonprescription Switches of 3 PPIs
August 3, 2018
- MHLW Orders Label Revisions for Otezla, Ceftriaxone
August 3, 2018
- Fusion of Registry Network and MID-NET Will Change Clinical Trial Landscape in Japan: MHLW Official
July 31, 2018
- Inappropriate Drug Promotion at Clinics Involves Encouragement of Off-Label Use in Most Cases: Study
July 31, 2018
- Boehringer’s DPP-4/SGLT2 Combo Clears MHLW Panel
July 30, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…